The objective was to evaluate efficacy/safety of complementary and alternative medicine (CAM) methods for generalized anxiety disorder (GAD) based on randomized controlled trials in adults.
Data sources. Six electronic databases (“generalized anxiety (disorder)” and “randomized trial”) and reference lists of identified publications were searched to March 2017. Study selection. Eligibility: full-text publications (English, German language); CAM versus conventional treatment, placebo/sham or no treatment; GAD diagnosed according to standard criteria; and a validated scale for disease severity. Of the 6693 screened records, 32 were included (18 on biologically-based therapies, exclusively herbal preparations; eight on manipulative and body-based therapies; and three on alternative medical systems and three on mind–body therapies). Data extraction. Cochrane Collaboration methodology was used for quality assessment and data extraction.
Direct comparisons of Kava Kava (Piper methysticum) extracts to placebo (4 quality trials, n = 233) were highly heterogeneous. Network meta-regression reduced heterogeneity and suggested a modest Kava effect [end-of-treatment Hamilton Anxiety scale score difference adjusted for baseline scores and trial duration: − 3.24 (95% CI − 6.65, 0.17; P = 0.059), Kava Kava 4 arms, n = 139; placebo 5 arms, n = 359]. Lavender (Lavandula angustifolia) extract (1 quality trial, 10 weeks, n = 523) and a combination of extracts of C. oxycantha, E. californica and magnesium (1 quality trial, 12 weeks, n = 264) were superior to placebo and balneotherapy was superior to paroxetine (1 quality trial, 8 weeks, n = 237) indicating efficacy. All other trials were small and/or of modest/low quality and/or lacked assay sensitivity. Safety reporting was poor.
Evidence about efficacy/safety of most CAM methods in GAD is limited. Apparent efficacy of certain herbal preparations and body-based therapies requires further confirmation.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of dsm-iii-r psychiatric disorders in the united states. Results from the national comorbidity survey. Arch Gen Psychiatry. 1994;51:8–19.
Nutt DJ, Kessler RC, Alonso J, et al. Consensus statement on the benefit to the community of ESEMeD (European study of the epidemiology of mental disorders) survey data on depression and anxiety. J Clin Psychiatry. 2007;68:42–8.
Stein M, Sherbourne C, Craske M, et al. Quality of care for primary care patients with anxiety disorders. Am J Psychiatry. 2004;161:2230–7.
Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month dsm-iv disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005;62:617–27.
Alonso J, Angermeyer M, Bernert S, et al. Prevalence of mental disorders in Europe: results from the European Study of the epidemiology of mental disorders (ESEMeD) project. Acta Psychiatr Scand. 2004;109:21–7.
Hidalgo RB, Tupler LA, Davidson JR. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol. 2007;21:864–72.
Schweitzer I, Maguire K, Ng C. Sexual side-effects of contemporary antidepressants: review. Aust N Z J Psychiatry. 2009;43:795–808.
Baldwin DS, Montgomery SA, Nil R, et al. Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol. 2007;10:73–84.
Foa EB, Franklin ME, Moser J. Context in the clinic: How well do cognitive-behavioral therapies and medications work in combination. Biol Psychiatry. 2002;10:987–97.
Baldwin DS, Polkinghorn C. Evidence-based pharmacotherapy of generalized anxiety disorder. Int J Neuropsychoph. 2005;8:293–302.
Liu L, Liu C, Wang Y, et al. Herbal medicine for anxiety, depression and insomnia. Curr Neuropharmacol. 2015;13:481–93.
Kinrys G, Coleman E, Rothstein E. Natural remedies for anxiety disorders: potential use and clinical applications. Depress Anxiety. 2009;26:259–65.
Garcia-Garcia P, Lopez-Munoz F, Rubio G, et al. Phytotherapy and psychiatry: bibliometric study of the scientific literature from the last 20 years. Phytomedicine. 2008;15:566–76.
Williams J, Gierisch J, McDuffie J, et al. An overview of complementary and alternative medicine therapies for anxiety and depressive disorders: supplement to efficacy of complementary and alternative medicine therapies for posttraumatic stress disorder. Evidence-based synthesis program. Washington: Department of Veterans Affairs; 2011:1–23.
Sarris J, Moylan S, Camfield DA, et al. Complementary medicine, exercise, meditation, diet, and lifestyle modification for anxiety disorders: a review of current evidence. Evid Based Complement Alternat Med. 2012;2012:809653.
Jorm AF, Christensen H, Griffiths KM, et al. Effectiveness of complementary and self-help treatments for anxiety disorders. Med J Aust. 2004;181:S29–46.
Sarris J, Goncalves D, Robins-Wahlins T, et al. Complementary medicine use by middle-aged and older women: personality, mood and anxiety factors. J Health Psychol. 2010;16:314–21.
Eisenberg D, Davis R, Ettner S, et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA. 1998;280:1569–75.
Unutzer J, Klap R, Sturm R, et al. Mental disorders and the use of alternative medicine: results from a national survey. Am J Psychiatry. 2000;157:1851–7.
Kessler R, Soukup J, Davis R, et al. The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am J Psychiatry. 2001;158:289–94.
Bazzan A, Zabrecky G, Monti D, et al. Current evidence regarding the management of mood and anxiety disorders using complementary and alternative medicine. Expert Rev Neurother. 2014;14:411–23.
Generalised anxiety disorder and panic disorder in adults: management | Guidance and guidelines | NICE. Niceorguk. 2017. Available at: https://www.nice.org.uk/guidance/cg113/chapter/1-Guidance#principles-of-care-for-people-with-generalised-anxiety-disorder-gad. Accessed April 25, 2017.
Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. BMJ. 2011;343:d5928.
IntHout J, Ioannidis JPA, Borm GF. The Hartung–Knapp–Sidik–Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Method. 2014;14:25.
Riley R, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549.
Kessels AGH, terRiet G, Puhan MA, et al. A simple regression model for network meta-analysis. OA Epidemol. 2013;1:7.
Brown H, Prescott R. Applied mixed models in medicine, 3rd ed, Wiley 2013:197-230.
Whitehead A. Meta-analysis of controlled clinical trials. New Jersey: Wiley; 2002. p. 131–6.
Volz H, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders—a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry. 1997;30:1–5.
Malsch U, Kieser M. Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. Psychopharmacology. 2001;157:277–83.
Connor K, Davidson J. A placebo-controlled study of Kava kava in generalized anxiety disorder. Int Clin Psychopharmacol. 2002;17:185–8.
Sarris J, Stough C, Bousman C, et al. Kava in the treatment of generalized anxiety disorder. J Clin Psychopharmacol. 2013;33:643–8.
Wheatley D. Kava-kava (LI 150) in the treatment of generalized anxiety disorder. Primary Care Psychia. 2001;7:97–100.
Boerner R, Sommer H, Berger W, Kuhn U, Schmidt U, Mannel M. Kava-Kava extract LI 150 is as effective as opipramol and buspirone in generalised anxiety disorder—an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients. Phytomedicine. 2003;10:38–49.
Woelk H, Schläfke S. A multi-center, double-blind, randomized study of the Lavender oil preparation Silexan in comparison to lorazepam for generalized anxiety disorder. Phytomedicine. 2010;17:94–9.
Kasper S, Gastpar M, Müller W, et al. Lavender oil preparation Silexan is effective in generalized anxiety disorder—a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol. 2014;17:859–69.
Herrera-Arellano A, Jiménez-Ferrer E, Zamilpa A, Morales-Valdéz M, García-Valencia C, Tortoriello J. Efficacy and tolerability of a standardized herbal product from Galphimiaglauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with Lorazepam. Planta Med. 2007;73:713–7.
Herrera-Arellano A, Jiménez-Ferrer J, Zamilpa A, García-Alonso G, Herrera-Alvarez S, Tortoriello J. Therapeutic effectiveness of Galphimiaglauca vs. lorazepam in generalized anxiety disorder. A controlled 15-week clinical trial. Planta Med. 2012;78:1529–35.
Amsterdam J, Li Y, Soeller I, Rockwell K, Mao J, Shults J. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (Chamomile) extract therapy for generalized anxiety disorder. J Clin Psychopharmacol. 2009;29:378–82.
Mao J, Xie S, Keefe J, Soeller I, Li Q, Amsterdam J. Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: a randomized clinical trial. Phytomedicine. 2016;23:1735–42.
Hanus M, Lafon J, Mathieu M. Double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegus oxyacantha and Eschscholtzia californica) and magnesium in mild-to-moderate anxiety disorders. Curr Med Res Opin. 2004;20:63–71.
Sayyah M, Siahpoosh A, Khalili H, Malayeri A, Samaee H. A double-blind, placebo-controlled study of the aqueous extract of Echium amoenum for patients with general anxiety disorder. Iran J Pharm Res. 2012;11:697–701.
Park D, Kim S, Park Y, Kang W, Lee S, Jung I. The comparative clinical study of efficacy of Gamisoyo-San (Jiaweixiaoyaosan) on generalized anxiety disorder according to differently manufactured preparations: Multicenter, randomized, double blind, placebo controlled trial. J Ethnopharmacol. 2014;158:11–7.
Akhondzadeh S, Naghavi H, Vazirian M, Shayeganpour A, Rashidi H, Khani M. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther. 2001;26:363–7.
Andreatini R, Sartori V, Seabra M, Leite J. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res. 2002;16:650–4.
Wang T, Ding J, Xu G, Zeng Y, Xiao S. Efficacy of Yiqiyangxin Chinese medicine compound combined with cognitive therapy in the treatment of generalized anxiety disorders. Asian Pac J Trop Med. 2012;5:818–22.
Eich H, Agelink M, Lehmann E, Lemmer W, Klieser E. AkupunkturbeileichtenbismittelschwerendepressivenEpisoden und Angststörungen–Ergebnisseeiner experimentellen Untersuchung. Fortschr Neurol Psychiatr. 2000;68:137–44.
Merom D, Phongsavan P, Wagner R, et al. Promoting walking as an adjunct intervention to group cognitive behavioral therapy for anxiety disorders— a pilot group randomized trial. J Anxiety Disord. 2008;22:959–68.
Dubois O, Salamon R, Germain C, et al. Balneotherapy versus paroxetine in the treatment of generalized anxiety disorder. Complement Ther Med. 2010;18:1–7.
Sherman K, Ludman E, Cook A, et al. Effectiveness of therapeutic massage for generalized anxiety disorder: a randomized controlled trial. Depress Anxiety. 2010;27:441–50.
Herring M, Jacob M, Suveg C, Dishman R, O’Connor P. Feasibility of exercise training for the short-term treatment of generalized anxiety disorder: a randomized controlled trial. Psychother Psychosom. 2012;81:21–8.
Ma H, Kui Y, Li Y, Huang B, Li S, Chen X. Bloodletting therapy combined with paroxetine hydrochloride for generalized anxiety disorder: A randomized controlled trial. 2013 IEEE International Conference on Bioinformatics and Biomedicine. 2013.
Jonsson K, Kjellgren A. Promising effects of treatment with flotation-REST (restricted environmental stimulation technique) as an intervention for generalized anxiety disorder (GAD): a randomized controlled pilot trial. BMC Complement Altern Med. 2016;16:108.
Rapaport M, Schettler P, Larson E et al. Acute Swedish massage monotherapy successfully remediates symptoms of generalized anxiety disorder. J Clin Psychiatry 2016:e883–e891.
Bonne O, Shemer Y, Gorali Y, Katz M, Shalev A. A randomized, double-blind, placebo-controlled study of classical homeopathy in generalized anxiety disorder. J Clin Psychiatry. 2003;64:282–7.
Tubaki B, Chandrashekar C, Sudhakar D, Prabha T, Lavekar G, Kutty B. Clinical efficacy of Manasamitra Vataka (an ayurveda medication) on generalized anxiety disorder with comorbid generalized social phobia: a randomized controlled study. J Altern Complement Med. 2012;18:612–21.
Gupta K, Mamidi P, Thakar A. Randomized placebo controlled study on Sarasvata choorna in generalised anxiety disorder. Int J Green Pharm. 2014;8:231–6.
Zhang Y, Young D, Lee S, et al. Chinese Taoist cognitive psychotherapy in the treatment of generalized anxiety disorder in contemporary China. Transcult Psychiatry. 2002;39:115–29.
Koszycki D, Raab K, Aldosary F, Bradwejn J. A multifaith spiritually based intervention for generalized anxiety disorder: a pilot randomized trial. J Clin Psychol. 2010;66:430–41.
Koszycki D, Bilodeau C, Raab-Mayo K, Bradwejn J. A multifaith spiritually based intervention versus supportive therapy for generalized anxiety disorder: a pilot randomized controlled Trial. J Clin Psychol. 2013;70:489–509.
Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry. 2002;3:171–99.
Bereza BG, Machado M, Ravindran AV, Einarson TR. Evidence-based review of clinical outcomes of guideline-recommended pharmacotherapies for generalized anxiety disorder. Can J Psychiatry. 2012;57:470–8.
Baldwin D, Anderson I, Nutt D, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28:403–39.
Mochcovitch M, da Rocha Freire R, Garcia R, Nardi A. Can long-term pharmacotherapy prevent relapses in generalized anxiety disorder? A Systematic Review. Clin Drug Investig. 2017;37:737–43.
Bandelow B, Seidler-Brandler U, Becker A, Wedekind D, Rüther E. Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry. 2007;8:175–87.
Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D. Efficacy of treatments for anxiety disorders. Int Clin Psychopharmacol. 2015;30:183–92.
Otto MW, Smits JA, Reese HE. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: review and analysis. Clin Psychol Sci Pract. 2005;27:572–81.
Kessler RC, Davis RB, Foster DF, et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med. 2001;135:262–8.
Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007, National health statistics reports; no 12.Hyattsville, MD: National Center for Health Statistics; 2008.
Fontenelle L, Santana. A review of studies concerning treatment adherence of patients with anxiety disorders. Patient Prefer Adherence. 2011;5:427–39.
Jonas WB. Policy, the public, and priorities in alternative medicine research. Ann Am Acad Polit Soc Sci. 2002;583:29–43.
Complementary and alternative medicine in the United States. 1st ed. Washington, DC: The National Academies Press; 2005.
Sarris J, Stough C, Teschke R, et al. Kava for the treatment of generalized anxiety disorder RCT: analysis of adverse reactions, liver function, addiction, and sexual effects. Phytother Res. 2013;27:1723–8.
Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, Gaboury I. Does the CONSORT checklist improve the quality of reports of randomized controlled trials? A systematic review. Med J Aust. 2006;185:263–7.
Nutt D, Allgulander C, Lecrubier Y, Peters T, Wittchen H. Establishing non-inferiority in treatment trials in psychiatry—guidelines from an Expert Consensus Meeting. J Psychopharmacol. 2008;22:409–16.
No funding or sponsorship was received for this study or publication of this article.
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Hrvoje Barić, Veljko Đorđević, Ivan Cerovečki, and Vladimir Trkulja have nothing to disclose.
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not involve any new studies of humans or animals performed by any of the authors.
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
To view enhanced content for this article go to https://doi.org/10.6084/m9.figshare.5896606.
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Barić, H., Đorđević, V., Cerovečki, I. et al. Complementary and Alternative Medicine Treatments for Generalized Anxiety Disorder: Systematic Review and Meta-analysis of Randomized Controlled Trials. Adv Ther 35, 261–288 (2018). https://doi.org/10.1007/s12325-018-0680-6
- Complementary and alternative medicine
- Generalized anxiety disorder
- Systematic review